Medication Adherence And Treatment Satisfaction In Patients Nursing Essay

medicine Adherence And Treatment atonement In foresighted- lows Nursing shewAbstractBackground and Objective Medication adhesion and intercession cheer be important for successful therapeutic issuecome. The objectives of this ruminate were to (1) evaluate major tranquilliser medicament chemical bond using 8-item Morisky Medication Adherence Scale (MMAS), (2) assess interference felicity using Treatment Satisfaction Questionnaire for Medication (TSQM 1.4), and (3) correlative affection and merriment with psychiatric symptoms measured using 24-item expanded shortened Psychiatric Rating Scale (BPRS-E) in longanimouss with schizophrenic psychosis.Methodology This is a jump sectional study Admin2010-12-25T100700Also, You should mention your design of study in lieu the textcarried show up at governmental out- persevering psychiatric unit in Nablus/ Palestine during pass 2010. Two hundred and sextupletty seven schizophrenic patients were registered at the clinic. Patients take in the study were those whose musics get under ones skin non been changed in the past six months and those who did not conduct an acute attack in the past course of study. info were entered and analyzed using SPSS 16 for windows.reticuloendothelial systemults One hundred and fifty patients Admin2010-12-25T124600In cross sectional study, you should calculate the sample size to bem using up a good precision for reliability and stiffness.These terms increase the character reference and acceptance commit of articles.out of 267 registered schizophrenic patients met the inclusion criteria. Nineteen patients ref utilise to put down musical composition 131 patients agreed giving a response outrank of 87.3%. The mean SD of MMAS was 6.1 1.7 in which 44 patients (33.6%) had scummy set up, 58(44.3%) had medium prise 29 (22.1%) had high rate of esteem to their neuroleptic agent medicinal drugs. The representation of satisfaction with go out to effective ness, gradient personal personal effects, toilet facility global satisfaction were 72.6 20.5, 67.9 31.47, 63.2 14.3 63.1 18.8 respectively. The mean BPRS score of the patients was 68.4 24.5 with 14.4 6.7 13.7 6.1 means for commanding and interdict symptoms gain ground respectively. Pearson correlativity showed that there was a positive and signifi shadowert coefficient of correlational statisticsal statistics amongst effectiveness (P = 0.002, r = 0.27), side effects (0.006, r =0.24), thingmabob (P Discussion and Conclusion conclusions rear be summarized as follows First, the bulk of the patients had low to medium rate of estimation. Second, bail was positively and crucially match with satisfaction. Third, regard was significantly but blackballly correlated with most psychiatric symptoms. Fourth, no significant struggle in bail was open up among patients receiving various major tranquillizer therapeutic regimes. Finally, various anti psychotic pabu lums significantly differ in side effects satisfaction domain only.Key words bail bond, satisfaction, psychiatric symptoms, antipsychotics gateSchizophrenia is a inveterate psychiatric disorder that impairs the quality of patients vivification and requires pharmacological and non-pharmacological interventions (Palmer et al., 2002 Pinikahana et al., 2002 Sharma and Antonova, 2003). Antipsychotic medicate therapy is considered as the key element in schizophrenic disorder counseling and has been account to minimize the frequency of acute schizophrenic episodes and hospitalization (Awad and Voruganti 2004 Campell et al., 1999). Adherence (compliance) to antipsychotic musics is necessary in order to arrive at these therapeutic goals. Furthermore, adherence has been account to lead to considerable cost nest egg (Damen et al., 2008). However, non-adherence (non-compliance) to antipsychotic medications is common and is considered as an integral barrier to the successful discussio n of schizophrenic psychosis (Dolder et. al, 2003 Weiden 2007 Byrne et al., 2006 Kim et al., 2006). There are several factors that can cause pr from each oneing non-adherence in schizophrenic patients. Such factors let in those derived from schizophrenic disorder itself, patient characteristics, those associated with the wellness-care system, and the antipsychotic treatment authorities (Svestka Bitter 2007 Misdrahi et al., 2002). Patients related factors contributing to non-adherence include gender, age, socio-economic status, race, and religion (Lowry 1998 Borras et al 2007). Cultural differences might be a potency factor for non-adherence. For example, a retrospect article nearly psychotropic medications found that evaluate of non-adherence were higher among Latinos than Euro-Americans and clinical and research interventions to improve adherence should be culturally appropriate and incorporate identified factors (Lanouette et al., 2009). Although patients satisfaction with treatment regimen is crucial for medication adherence (Atkinson et al., 2004 Taira et al. 2006), hardly a(prenominal) studies had examined the birth betwixt adherence, treatment satisfaction and therapeutic outcome in patients with schizophrenia (Fujikawa et al. 2004 Freudenreich et al., 2004 Watanabe et al, 2004).Therefore, the objectives of this study were to(1) Assess the degree of adherence to antipsychotic medications among schizophrenic outpatients using eight-item Morisky Medication Adherence Scale (MMAS),(2) Assess the degree of patients satisfaction with their treatment regimen using Treatment satisfaction Questionnaire for medication (TSQM 1.4),(3) Evaluate patients clinical symptoms, positive Symptom Score (PSS) Negative Symptom Score (NSS) using outline Psychiatric Rating Scale (BPRS), and finally(4) Investigate relationships and correlations amid medication adherence, subjective patients treatment satisfaction and psychiatric symptoms in patients with schizophreni a.Methodology2.1. Patient selectionThis study was conducted amid July 2010 familytember 2010 at Al-Makhfya psychiatric health Center in Nablus, Palestine. Approval to perform the study was obtained from the Palestinian ministry of health and IRBAdmin2010-12-25T100900Define this abbreviation committee at An-Najah National University. Patients who met the spare-time activity criteria were invited to trigger officipate in this study 1) their age was between 20 65 years, 2) they were diagnosed with schizophrenia as defined by DSMAdmin2010-12-25T132900Define this abbrev.-IV, 3) they had not been suffering from an acute attack of illness during the past year, and 4) their drug regimen had not been changed in the past 4 months.2.2. Assessment and measuresThe instrument used in this study consisted of three parts part one collected socio-demographic and medication info from patients medical files part two was the Arabic interlingual rendition of the clear eight-item Morisky Medicat ion Admin2010-12-25T133100. The final version of the Arabic questionnaire should be assessed to admit if the Arabic version is reliable and valid to be used in your population. This a routine question by high impact daylightbookAlso, I suppose you are the first who use this score in Arab country, and this is good for you because you can write new article related to stiffness and reliability and it is preferred to be published before this article.Adherence Scale (MMAS) (Morisky et al., 2008, Morisky et al., 1986) and part three was the Arabic version of Treatment Satisfaction Questionnaire for Medication (TSQM 1.4) which the researchers obtained from Quintiles strategical Research Services. The side version of the MMAS was translated into Arabic and was approve by professor Morisky through e-mail communication. The displacement reaction process was carried out consort to the following procedure 1) A forward adaptation of the original questionnaire was carried out from Engli sh to Arabic language to produce a version that was as scraggy as possible to the original questionnaire in concept and meaning. Translation was carried out by two qualified independent translators both native speakers of Arabic and proficient in English. Each translator produced a forward translation of the original questionnaire into Arabic language without any mutual consultation. The corresponding author, who is a native Arabic speaker, reviewed the two primary versions and compared them with the original. (2) A back translation from Arabic language to English was carried out by two una uniform translators after lengthy discussion between the translators and the corresponding author. (3) The back translated questionnaire was approved by Professor Donald Morisky through e-mail. The Arabic version of MMAS is an 8-item questionnaire with 7 yes/no questions while the last question was a 5-point likert question. Based on the grading system of MMAS, adherence was rated as follows h igh adherence (= 8), medium adherence (6 The TSQM 1.4 is a 14-item psychometrically robust and validated instrument consisting of four scales Bahramal et al., 2009. The four scales of the TSQM 1.4 include the effectiveness scale (questions 1 to 3), the side effects scale (questions 4 to 8), the convenience scale (questions 9 to 11) and the global satisfaction scale (questions 12 to 14). The TSQM 1.4 domain scores were calculated as recommended by the instruments authors, which is described in detail elsewhere (Atkinson et al., 2004 Atkinson et al., 2005). The TSQM 1.4 domain scores range from 0 to century with higher scores representing higher satisfaction on that domain.Psychiatric symptoms, positive and interdict schizophrenic symptoms were evaluated by a psychiatrist and well educate psychologists using the expanded Brief Psychiatric Rating Scale (BPRS-E) ( boilers suit and Gorham, 1962 Overall 1988 Lukoff et al., 1986 Ventura et al, 1993) at the same visit. The BPRS-E consist s of 24 items measuring psychiatric symptoms. It measures four various dimensions manic excitement/ disorganization, positive symptoms, negative symptoms, and depression/ anxiety (Ruggeri et al., 2005). unconditional symptoms were the followings grandiosity, suspiciousness, hallucinations, unusual thought content and conceptual disorganization. Negative symptoms included disorientation, weaken affect, emotional withdrawal, motor retardation, and mannerism and posturing.2.3. Data analysisContinuous variables like Morisky score, satisfaction domain scores, BPRS, positive and negative symptoms scores were expressed as mean SD. Correlation between continuous variables was carried out using Pearson correlation assay. Difference in means was carried out using one-way analysis of variance test. All statistical analyses were conducted using Statistical Package for Social Sciences (SPSS version 16.0) for Windows. The conventional 5 percent import level was used end-to-end the study.Re sultsDemographic and clinical characteristics of patientsOne hundred and fifty patients out of 267 registered schizophrenic patients met the inclusion criteria. One hundred and thirty one (131) patients agreed to record giving a response rate of 87.3%. Of the 131 patients, 40 (30.5%) were female and 91 (69.5%) were male. The mean age of the patients was 42.9 10.3 years (range = 20 65 years). The mean time of illness was 16.23 9.59 years. Eighteen patients (13.7%) had other non-psychiatric diseases mainly diabetes mellitus (10 patients 7.6%). Smoker schizophrenic patients delineate 55% (72 patients) of the sample. None of the patients were account to get under ones skin any suit of drug abuse. Details regarding demographic and clinical characteristics of the studied patients are shown in submit 1.Regarding treatment regimens, patients were grouped into 7 categories based on the causa of antipsychotic medications they were using Twenty four patients (18.3%) had been treated with ad-lib typic antipsychotics only, 8 patients (6.1%) were using combination literal examination exemplary antipsychotics, 19 (14.5%) had been treated with classifiable endpoint injections only, 37 (28.2%) had been treated with veritable(prenominal) oral and depot injections, 18 (13.7%) had been treated with oral unorthodox only, 12 patients (9.2%) had been treated with typical and unrepresentative oral antipsychotics, and finally 13 patients (9.9%) had been treated with uncharacteristic oral and typical depot injection combination. The most common oral typical antipsychotic used by the patients was chloropromazine while the most common atypical antipsychotic was clozapine.Based on MMASAdmin2010-12-25T133400It is preferred to classify the characteristic of patients according to the adherence groups. Also, indicate if there is differences between the 3 groups , 44 (33.6%) of patients were rated as having low adherence, 58 (44.3%) were rated as having medium adherence 29 (22.1%) were rated as having high adherence to their antipsychotic medications. The average adherence score (6.1 1.7) for the patients largely indicates medium rate of adherence. Upon investigation using 8-item Morisky scale (questionnaire ), we found that about 33.6% of patients forgot to take their medications 15.3% of patients missed taking their medication for reason other than forgetting in the past two weeks before the interview 13.7% stopped taking their medication without doctor counseling when they felt worse upon taking them 16.8% forgot to take their medications with them when they abjure home for long time 10.7% didnt take their medication in the day before interview 26% stopped taking their medication when they felt that their health is under control and 55.7% felt hassled about sticking to their treatment plan. As for remember to take their medications 27.5% of the patients approach a difficulty in doing this once in a while 6.1% of the sample sometimes had di fficulties in remembering to take their medications 6.9% of patients usually found difficulties while 0.8% of schizophrenic patients faced these difficulties all the times. However 58.8% didnt show any difficulty in remembering to take their medication on time. Response to each question in the modified Morisky questionnaire is shown in Table 2.The average score of satisfaction with regard to effectiveness, side effects, convenience global satisfaction was 72.6 20.5 67.9 31.5 63.2 14.3 63.1 18.8 respectively. The mean BPRS score of the patients was 68.4 24.5 with 14.4 6.7 13.7 6.1 means for positive and negative symptoms scores respectivelyCorrelation between adherence scores and other variablesThere was a significant positive correlation between age and adherence (P = 0.028 r = 0.19Admin2010-12-25T133500As recommended, when correlation is less than 0.25 this considered as no or week correlation, 0.25-0.50 considered fair correlation. You can take this comments in your consi deration.). However, no such correlation was observed with the date of illness (P = 0.13). Furthermore, no significant difference in the means of adherence was found between male and female (P = 0.76). Patients having other chronic diseases have significantly higher adherence score compared to those who do not, but the significance was at the borderline (P = 0.049).Pearson correlation showed that there was a positive and significant correlation between all satisfaction domains like effectiveness (P = 0.002, r = 0.27), side effects (P= 0.006, r =0.24), convenience (P Adherence, Treatment Satisfaction and type of antipsychotic regimenAdherence score was not significantly assorted (P = 0.6) among patients having different antipsychotic therapeutic regimens. Analysis of satisfaction based on the antipsychotic drug regimens showed that there was a significant difference in satisfaction with regard to side effects among different antipsychotic regimens ( P = 0.006, F = 3Admin2010-12-25T 133500When you use one way ANOVA, it is recommended to use the Tukey post-hoc test to test the differences in the means between categories. To determine which group or groups are significant.). Patients on atypical antipsychotic drug therapy showed the highest satisfaction with side effects (86.5 4.8) compared with (51.3 5.17) to those on typical antipsychotic mono-therapy. No significant difference with regard to other satisfaction domains (effectiveness, convenience and global satisfaction) among patients with different psychiatric regimens. Similarly no significant difference was found in BPRS scores (P = 0.6), positive (P = 0.6) and negative symptoms (P= 0.8) among different antipsychotic drug regimens. Details regarding adherence scores, BPRS, positive and negative symptoms with different antipsychotic drug regimens are shown in Table 4.DiscussionThis studyAdmin2010-12-25T133600This study is the first of its type in Palestine and the first study used an Arabic version for Mor isky. You can add this points as originality of the article was conducted to assess medication adherence and treatment satisfaction among schizophrenic outpatients. The conclusions of the study can be summarized as follows First, the majority (78%) of the patients had low to medium adherence rate. Second, adherence was positively and significantly correlated with treatment satisfaction. Third, adherence was significantly correlated with positive but negative psychiatric symptoms. Fourth, no significant difference in rate of adherence was found between patients using typical or atypical antipsychotic therapeutic regimens. Finally, patients on typical or atypical antipsychotic medications had analogous scores in all domains of satisfaction except for that of side effects.Regarding rate of adherence, several studies have shown that up to 80% of all schizophrenic patients halt antipsychotic medications and that non-adherence rates ranging from 20% to 89%, with an average rate of near 50%, have been reported (Fenton et al, 1997 Lacro et al 2002, Young et al, 1986). Differences in rate of adherence among different reports might be attributed to different instrument used to assess adherence, social and cultural differences among different countries and differences in healthcare systems (Breen et al., 2007). In our study, junior patients had significantly cut adherence score than elderly patients. This conclusion is in agreement with other researchers who reported that younger schizophrenic patients have lesser adherence than older patients (Sajatovic et al 2007 Hui et al reported that younger age is a forecaster for discontinuation of antipsychotic therapy (Hui et al. 2006). However, other researchers reported equal non adherence among middle aged and elderly patients (Jeste et al., 2003) . Many factors have been cited as a potential cause for poor adherence. Side effects are key factors influencing compliance with antipsychotic medication (Weiden et al., 2004 ). (Liu-Seifert et al., 2005 Fleischhacker et al., 2003).There are few reports suggesting that treatment satisfaction is positively associated with antipsychotic medication adherence Gharbawi et al., 2006,, amend clinical outcomes Masand and Narasimhan, 2006, and quality of life Hofer 2004,. Our leave behinds give further erect that treatment satisfaction is positively associated with adherence and symptom improvement, particularly psychotic positive symptoms. A study by Maneesakorn 2008 indicated that antipsychotic medication adherence has positive impact on psychiatric symptoms and satisfaction with medication (Maneesakron et al., 2007). Furthermore, Mohamad et al 2009 demonstrated an association between positive attitudes toward medication among schizophrenia patients and lower rates of study discontinuation (Mohamed et al., 2009). Thus, it is important to accurately evaluate patient satisfaction with medication treatment using validated instruments that can be utilized in cli nical trials and practice. Medication non-adherence had a significantly negative impact on treatment response, highlighting the importance of adherence to gain satisfactory treatment outcome (Lindameyr et al., 2009). A study by Liu-Seifert et al 2005 has found that discontinuing of treatment may lead to exacerbation of psychiatric symptoms and undermining therapeutic progress (Liu-Seifert et al., 2005). In these studies, poor response to treatment and worsening of underlie psychiatric symptoms, and to a lesser extent, intolerability to medication were the primary contributors to treatment macrocosm discontinued.Fewer extrapyramidal symptoms and tardive dyskinesia of atypical compared to typical antipsychotics led researchers to speculate that patients receiving atypical antipsychotics will show greater adherence, satisfaction and psychiatric improvement compared to patients receiving typical antipsychotics (Kane et al., 1988 Tollefson et al., 1997 Marder et al., 1994 Small et al. , 1997 Jeste et al., 1999 Marder SR, 1998). However, our findings regarding adherence, satisfaction and psychiatric symptoms measured by BPRS-E were similar between patients on typical and atypical antipsychotic medications. Rosenheck and colleagues evaluated medication continuation and regimen adherence in 423 patients taking haloperidol or clozapine as part of a double-blind, randomized trial. Although the patients who received clozapine continued their medication significantly longish, the treatment groups did not differ in the proportion of pills returned each week (Rosenheck et al., 200). Olfson and colleagues examined the effect of antipsychotic type on adherence 3 months after 213 inpatients with schizophrenia or schizoaffective disorder were discharged while receiving typical (84.5% of patients) or atypical (14.5% of patients) antipsychotics. A non-significant trend toward increased adherence was reported among patients with prescriptions for atypical antipsychotics (Olfson et al., 2000). Cabeza and colleagues retrospectively studied the relationship of adherence to antipsychotic type in 60 inpatients with schizophrenia. No significant association was found between adherence and type of antipsychotic (Cabeza et al., 2000). Dolder reported that patients on either typical or atypical had similar low rates of adherence (Dodler et al., 2002). Gianfransessco et al 2006 indicated that none of the atypicals showed treatment durations significantly different from the typical (Gianfransessco et al 2006). A study by Jones et al, 2006 has found that in people with schizophrenia whose medication is changed for clinical reasons, there is no disadvantage across 1 year in terms of quality of life, symptoms, or associated costs of care in using FGAs rather than nonclozapine SGAs (Jones et al., 2006). Schulte et al concluded that, in general, very few or no advantages are to be gained from using SGAS rather than FGAS and the clinical effectiveness is not increased, bu t the side-effects are different. (Schulte et al 2010). In contrast, Al-Zakawani reported that atypical antipsychotic users were significantly more adherent to therapy, and had lower rates of office, hospital and emergency room utilization (Al-zakawani 2003). Actually, efficacy variations within SGAs and FGAs result in overlaps between the two groups and classification of antipsychotics into the two groups is no longer useful (Volvoka 2009). One might argue that cost of atypical antipschyotics is the barrier for medication adherence (Gibson et al., 2010). However, in our study, all patients had governmental insurance and so cost of medications was not a reason of poor adherence of atypical antipsychotics.Regarding results of depot IM antipsychotic injections, we found no difference between oral and long acting antipsychotics with regard to adherence, satisfaction or psychiatric symptoms. some researchers reported similar or better adherence, satisfaction and outcome with long acti ng injection than oral antipsychotics (Olivares et al., 2009 Gutierrez et al., 2010 Kane and Garcia 2009 Haddad et al., 2009). In contrast, vehof reported that patients on depot antipsychotics were less adherent and have more side effects than oral antipsychotics (Vehof et al., 2008).Our study has few demarcations. The sample size might be relatively small to draw conclusions for assessing adherence, satisfaction and psychiatric symptoms. Instruments that we used to assess adherence, satisfaction and BPRS are might not be the gold standard for this purpose. A third Admin2010-12-25T131600Must be preceded by first and secondpotential limitation of our study is that the patients selected were homogenous in that all of them had governmental insurance and tends to use similar medications. Non-adherence among schizophrenic patients might be inherent in the stage setting of the disease itself. Despite these limitations, results of this study were useful in understanding adherence, satis faction and psychiatric symptoms.ReferencesAdmin2010-12-25T104500The number of references is too much, after delete the retell ref. the number still 75Al-Zakwani IS, Barron JJ, Bullano MF, Arcona S, Drury CJ, Cockerham TR. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin. 200319(7)619-26.Arana GW An overview of side effects caused by typical antipsychotics.J Clin Psychiatry 2000 615-11Atkinson MJ, Kumar R, Cappelleri JC, Hass SL Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value health 2005, 8(Suppl 1)S9-S24.Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. institution of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. wellness Qual Life Outcomes. 2004 Feb 26212Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.. CNS Drugs. 200418(13)877-93. ReviewBharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. wellness Qual Life Outcomes. 2009 Apr 27736Borras L, Mohr S, Brandt PY, Gilliron C, Eytan A, Huguelet P. Religious beliefs in schizophrenia their relevance for adherence to treatment. Schizophr Bull. 2007 Sep33(5)1238-46Breen A, Swartz L, Joska J, Flisher AJ, Corrigall J. Adherence to treatment in poorer countries a new research direction? Psychiatr Serv. 2007 Apr58(4)567-8Byrne MK, Deane FP, Caputi P. Mental health clinicians beliefs about medicines, attitudes, and expectations of improved medication adherence in patients. Eval Health Prof. 2008 decline31(4)390-403Cabeza IG, Amador MS, Lopez CA, Chavez MG essential response to a ntipsychotics in schizophrenic patients clinical implications and related factors. Schizophr Res 2000 41349-355Campbell M, Young PI, Bateman DN, Smith JM, Thomas SH The use of atypical antipsychotics in the management of schizophrenia.. Br J Clin Pharmacol. 1999 Jan47(1)13-22. ReviewClinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients results from a multinational electronic registry. Curr Med Res Opin. 2009 Sep25(9)2197-206Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients. Manag Care. 2010 Aug19(8)40-7Damen J, Thuresson PO, Heeg B, Lothgren M. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Appl Health Econ Health Policy. 20086(4)189-97.De Hert M, McKenzie K, Peuskens J. Risk factors for suicide in young people suffering from schizophrenia a long-term follow-up study. Schizophr Res. 2001 Mar 147(2-3)127-34Ding emans PM, Linszen DH, Lenior ME, Smeets RM. destiny structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacology (Berl). 1995 Dec122(3)263-7Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence is there a difference between typical and atypical agents? Am J Psychiatry. 2002 Jan159(1)103-8. Erratum in Am J Psychiatry 2002 Mar159(3)514Dolder CR, Lacro JP, Jeste DV. Adherence to antipsychotic and nonpsychiatric medications in old and older patients with psychotic disorders. Psychosom Med. 2003 Jan-Feb65(1)156-62.Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence review of recent literature. J Clin Psychopharmacol. 2003 Aug23(4)389-99. ReviewFenton WS, Blyler CR, Heinssen RK Determinants of medication compliance in schizophrenia empirical and clinical findings. Schizophr Bull 1997 23637-651Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Cli n Psychiatry. 200364 Suppl 1610-3Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications relationship to clinical variables and insight. J Clin Psychiatry. 2004 Oct65(10)1372-6Fujikawa M, Togo T, Yoshimi A, Fujita J, Nomoto M, Kamijo A, Amagai T, Uchikado H, Katsuse O, Hosojima H, Sakura Y, Furusho R, Suda A, Yamaguchi T, Hori T, Kamada A, Kondo T, Ito M, Odawara T, Hirayasu Y. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008Gharabawi GM, Greenspan A, Rupnow MF, Kosik-Gonzalez C, Bossie CA, Zhu Y, Kalali AH, Awad AG. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia data from a randomized double-blind trial. BMC Psychiatry. 2006 Oct 20645Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res. 2006 Nov 15144(2-3)177-89. Epub 2006 Sep 27.Gibson TB, Jing Y, Kim E, Bagalman E, Wang S, Whitehead R, Tran QV, Doshi JA.Gutirrez-Casares JR, Caas F, Rodrguez-Morales A, Hidalgo-Borrajo R, Alonso-Escolano D. Adherence to treatment and therapeutic strategies in schizophrenic patients the ADHERE study. CNS Spectr. 2010 May15(5)327-37.Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl. 2009 Nov52S20-8.Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003 Jul-Aug12(5)423-4.Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 20 04 Jul65(7)932-9Hui CL, Chen EY, Ka